-
Mashup Score: 1
According to Genereux, asymptotic severe aortic stenosis (AS) is associated with poor prognosis, especially when a patient has an abnormal stress test. However, better evidence is needed to determine how to best manage these patients. “Obviously TAVR has been shown to be equal to surely in some patients, and now what we are doing is investigating the need to intervene earlier in patients, not…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
A decade ago, when transcatheter aortic valve replacement (TAVR) was first cleared by the U.S. Food and Drug Administration (FDA), many expected TAVR would only be used in a small portion of patients, and surgeons had concerns about losing business. A decade on, the unexpected happened, and it turns out with TAVR, everyone is a winner, including the patient, interventional cardiologist, hospitals…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Cardiac surgeons gaining procedural volume despite TAVR making up 84% of cases #cardiotwitter #structuralheart #TAVR #TAVI #SAVR #TVT #TVT2022 #TVT22 #TCT22 #TCT2022 https://t.co/JxUfNG827y
-
-
Mashup Score: 3
She said this year’s TVT was exciting because it was the first in-person meeting since 2019, and there was a lot of new technology discussed in sessions. This included first reports on clinical use of new technologies for the mitral valve and tricuspid valve. “The question is which ones will come out in the wash and which of these technologies will become the most successful,” Asgar said. “We…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
VIDEO: Advances in transcatheter tricuspid and mitral valve technology #heartfailure #TVT22 #TVT2022 #structuralheart #cardiotwitter #cardiology https://t.co/bYaAkXu7oI
-
-
Mashup Score: 2VIDEO: Advances in left atrial appendage occlusion technology - 2 year(s) ago
She discusses the two FDA cleared LAA occlusion (LAAO) devices, the Boston Scientific Watchman FLX and the Abbott Amulet, and new devices in development or already in trials. These include the CLAAS Conformal, Laminar, LAmbre and devices that may combine ablation with LAAO. Nair also discusses use of CT imaging to help size and preplan the LAA closure procedures and how transesophageal echo…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
VIDEO: Advances in left atrial appendage occlusion technology #cardiotwitter #EPeeps #LAA #LAAO #TVT #TVT2022 #structuralheart https://t.co/mCfrZ1MaSq
-
-
Mashup Score: 1VIDEO: Transcatheter tricuspid devices likely to gain FDA clearance before new mitral advances - 2 year(s) ago
It was clear at TVT that tricuspid valve therapies will likely move ahead of new mitral therapies coming to market. Several structural heart thought leaders, including Latib, shared this opinion, saying the tricupid is an easier valve to problem solve for, having the more complex anatomy and higher pressure environment of the left ventricle. The tricuspid valve is certainly no longer the…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
VIDEO: Transcatheter tricuspid devices likely to gain FDA clearance before new mitral advances #TVT #TVT22 #TVT2022 @crfheart #TMVR #TTVR #structuralheart https://t.co/XAJIYHtpfV
-
-
Mashup Score: 0
Brian Ghoshhajra, MD, MBA, division chief, cardiovascular imaging, Massachusetts General Hospital and associate professor of radiology, Harvard Medical School, and a board member of the Society of cardiovascular Computed Tomography (SCCT), explains the rapidly expanding interest in cardiac computed tomography (CT) under the new chest pain evaluation guidelines.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Links to all the late-breaking structural heart studies at TVT 2022 #cardiotwitter #TVT22 #TVT2022 @crfheart https://t.co/hOSlgkQpVT
-
-
Mashup Score: 0VIDEO: How to build a structural heart program - 2 year(s) ago
He explained the key elements required include: 1. Champion interventional cardiologists and cardiac surgeons who can work together as a team and share decision making for what is best for the patient. 2. Interventional imagers who can work as a key part of the team for pre-procedural evaluations and guide imaging during procedures. This is usually a dedicated interventional…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
VIDEO: How to build a structural heart program #TVT #TVT22 #TVT2022 #cardiotwitter #structuralheart #TAVR #TMVR @NorthwesternMed https://t.co/NFvmThsrD2
-
-
Mashup Score: 0
Many unanswered questions remain regarding devices for tricuspid regurgitation
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Experts discussed replacement or repair when it comes to transcatheter technologies in the tricuspid space. By @nicolejlou, @MedPageCardio. @GAilawadiMD @GilbertTangMD @mszerlip #cardiotwitter @crfheart #TVT2022 https://t.co/q8ujJDUbZQ
-
-
Mashup Score: 0
After left atrial appendage occlusion with a next-generation device, patients with atrial fibrillation had similar outcomes at 45 days regardless of medication regimen, researchers reported at TVT: The Structural Heart Summit.From a database of patients who underwent left atrial appendage (LAA) occlusion with the next-generation device (Watchman FLX, Boston Scientific) and were included in the
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “There was no difference in death, stroke, bleeding or device-related thrombosis between DAPT and DOAC plus aspirin or warfarin plus aspirin at 45 days following LAA occlusion with Watchman FLX,” #TVT2022 @MCoylewright @erlangerhealth #CardioTwitter https://t.co/NKYXBcUrVT
-
-
Mashup Score: 0
After left atrial appendage occlusion with a next-generation device, patients with atrial fibrillation had similar outcomes at 45 days regardless of medication regimen, researchers reported at TVT: The Structural Heart Summit.From a database of patients who underwent left atrial appendage (LAA) occlusion with the next-generation device (Watchman FLX, Boston Scientific) and were included in the
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “There was no difference in death, stroke, bleeding or device-related thrombosis between DAPT and DOAC plus aspirin or warfarin plus aspirin at 45 days following LAA occlusion with Watchman FLX,” #TVT2022 @MCoylewright @erlangerhealth #CardioTwitter https://t.co/NKYXBcUrVT
-
VIDEO: TAVR for asymptomatic patients with severe calcific aortic stenosis #TAVR #structuralheart #TAVI #Cathlab #TVT22 #TVT2022 @PhilGenereuxMD https://t.co/tOQsQ4QJfX